Clinical trials: Cancer Disease
Polycystic Ovary Syndrome
Auricular Acupressure (AA) For Overweight/Obese Adolescent and Young Polycystic Ovary Syndrome ( PCOS)
The purpose of this trial is to investigate the effect and safety of auricular acupressure on adolescent and young women with PCOS.
- Trial name
- NCT02326714
- Testing
- Auricular acupressure
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Heilongjiang University of Chinese Medicine
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT04647916
- Testing
- Sacituzumab Govitecan
- Where
- 296 sites in United States
- Volunteers
- 44 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
This study will help to understand the interaction between estrogen receptor-alpha (ER alpha) and tumor suppressor protein p53 as well as impact on patient tumor gene expression in response to the hormonal therapy Tamoxifen.
- Trial name
- NCT01027416
- Testing
- Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
This phase I/II trial studies the side effects and best dose of genetically modified T cells in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma.
- Conditions
- Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pleural Malignant Mesothelioma
- Trial name
- NCT02408016
- Testing
- Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity levels and quality of life in patients with stage II…
- Conditions
- Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT06855706
- Testing
- Behavioral Intervention, Best Practice, Biospecimen Collection
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Roswell Park Cancer Institute
Non-Hodgkin's Lymphoma, B-cell Lymphoma
R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma
This study evaluates the use of the standard treatment R-CHOP plus the anti-VEGF drug, bevacizumab and whether this treatment is feasible in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT00788606
- Testing
- bevacizumab, Rituximab
- Where
- 2 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Pancreatic Cancer
Study of Ruxolitinib in Pancreatic Cancer Patients
The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.
- Trial name
- RECAP (NCT01423604)
- Testing
- Capecitabine, Ruxolitinib
- Where
- 39 sites in United States
- Volunteers
- 136 people
- Sponsor
- Incyte Corporation
Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation
Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy
People having radiation therapy to the head and neck often develop painful mouth problems - mouth sores, dry mouth, mouth pain, trouble eating and drinking, and changes in taste.
- Conditions
- Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation, Stomatitis (Oral Mucositis), Xerostomia Due to Radiotherapy
- Trial name
- OSEM (NCT07885033)
- Testing
- ORAL CARE PRODUCT KIT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UNCANCER LLC
Recurrent Vulvar Cancer, Persistent Vulvar Cancer
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.
- Conditions
- Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer, Locally Advanced Vulvar Cancer
- Trial name
- PIERCE (NCT05903833)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 15 sites in Germany
- Volunteers
- 42 people
- Sponsor
- AGO Research GmbH
Rectal Cancer, Radiotherapy
Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer
This is a open-label, single-arm study to investigate the safety and efficacy of consolidative chemotherapy with camrelizumab, an anti-PD-1 antibody drug following short course radiotherapy and subsequent surgical therapy in…
- Conditions
- Rectal Cancer, Radiotherapy, Immunotherapy
- Trial name
- NCT04231552
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
The main purpose of this first study combining an investigational dual mTOR inhibitor, CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to establish a maximum tolerated dose level for each…
- Trial name
- NCT01545947
- Testing
- CC-223, erlotinib, CC-223, oral azacitidine
- Where
- 9 sites in United States, Spain
- Volunteers
- 76 people
- Sponsor
- Celgene
Wilms Tumour
Collaborative Wilms Tumour Africa Project
Significant progress has been made in the treatment of Wilms tumor in high income countries, where survival is now around 85% - 90%.
- Trial name
- NCT01991652
- Where
- 3 sites in Cameroon, Ghana and 1 more
- Volunteers
- 400 people
- Sponsor
- Amsterdam UMC, location VUmc
Lung Diseases, Carcinoma, Non-Small-Cell Lung
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
Open-label, non-randomized, phase II multi-centre controlled clinical trial. 51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment…
- Conditions
- Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- APOLO (NCT04776447)
- Testing
- Carboplatin, Placlitaxel, Atezolizumab
- Where
- 22 sites in Spain
- Volunteers
- 38 people
- Sponsor
- Fundación GECP
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.
- Trial name
- ADAURA2 (NCT05120349)
- Testing
- Osimertinib
- Where
- 139 sites in United States, Argentina and 18 more
- Volunteers
- 390 people
- Sponsor
- AstraZeneca
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with…
- Conditions
- Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
- Trial name
- NCT02912949
- Testing
- zenocutuzumab (MCLA-128)
- Where
- 64 sites in United States, Austria and 16 more
- Volunteers
- 250 people
- Sponsor
- Partner Therapeutics, Inc.
Breast Cancer, Chemotherapy-induced Nausea and Vomiting
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Chemotherapy is one of the most common treatments for breast cancer, but the adverse effects can be severe enough to delay or make chemotherapy intolerable, thus affecting the efficacy of the disease.
- Trial name
- NCT05841849
- Testing
- Aprepitant, Palonosetron, Fosaprepitant
- Where
- China
- Volunteers
- 1,028 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer
Phase I trial to study the effectiveness of gene therapy plus chemotherapy in treating patients who have breast cancer. Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make…
- Trial name
- NCT00004038
- Testing
- Ad5CMV-p53 gene, chemotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Pain Postoperative
Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
This phase III, randomized, prospective clinical study, aiming to compare the analgesic effects of celecoxib, parecoxib, and oxycodone in patients with inoperable hepatic carcinoma undergoing TACE procedure in postoperative pain…
- Trial name
- NCT03059238
- Testing
- Celecoxib 200mg oral capsule, parecoxib sodium, controlled-release oxycodone
- Where
- China
- Volunteers
- 213 people
- Sponsor
- Sun Yat-sen University
Ovarian Neoplasms, Breast Neoplasms
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
To determine the safety and immunogenicity profile of two (2) different doses of the vaccine DPX-0907 to treat breast, ovarian and prostate cancer.
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT01095848
- Testing
- DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Advanced Malignancies, Ovarian Cancer
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy.
- Conditions
- Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
- Trial name
- NCT04752826
- Testing
- BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection, Paclitaxel 80 mg/m2 weekly
- Where
- 25 sites in United States, Denmark and 5 more
- Volunteers
- 250 people
- Sponsor
- BioInvent International AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.